Residency · Residency · Medicine Pediatrics

Sickle Cell Disease: Bridging Pediatric and Adult Hematology

Overview

Sickle cell disease (SCD) is the most common inherited hemoglobinopathy worldwide. Advances in pediatric care (newborn screening, penicillin prophylaxis, transcranial Doppler screening) have dramatically improved childhood survival, but a sharp mortality spike occurs during the transition to adult care in early adulthood. Med-Peds physicians are critical to bridging this gap.

Genetics and Pathophysiology

Autosomal recessive; caused by a point mutation in the beta-globin gene (Glu6Val) Hemoglobin S (HbS) polymerizes under deoxygenation, causing red cell sickling. Pathophysiology involves vaso-occlusion, hemolytic anemia, endothelial dysfunction, and chronic inflammation. Genotypes: HbSS (sickle cell anemia): most severe. HbSC: intermediate severity, higher risk of proliferative retinopathy and avascular necrosis. HbS-beta-thalassemia: severity depends on beta-thal type (beta-zero mimics SS; beta-plus is milder) HbS with other variants (HbSD, HbSO-Arab)

Newborn Screening and Early Pediatric Management

Universal newborn screening in all 50 US states since 2006. Hemoglobin electrophoresis pattern: FS (sickle cell disease), FAS (sickle trait), FSC (HbSC) Penicillin prophylaxis: begin by 2 months of age, continue until at least age 5. PROPS trial (1986): 84% reduction in pneumococcal sepsis. Pneumococcal vaccination: PCV13 series + PPSV23. Parental education on splenic sequestration (palpating the spleen) Transcranial Doppler (TCD) screening: annually ages 2-16. STOP trial: chronic transfusion reduces stroke risk from 10% to <1% in children with elevated TCD velocities (>200 cm/s)

Acute Complications

Vaso-Occlusive Crisis (VOC)

Most common reason for ED visits and hospitalization. Triggered by cold, dehydration, infection, stress, hypoxia. Management: aggressive hydration, multimodal analgesia, incentive spirometry. Pain management differences between pediatric and adult settings: Pediatric: intranasal fentanyl, weight-based dosing, child life specialists. Adult: often faces stigma, opioid stewardship concerns, longer wait times. Bias and racism in pain management is well-documented.

Acute Chest Syndrome (ACS)

Leading cause of death in SCD. Defined by new pulmonary infiltrate + respiratory symptoms or fever. Etiology: infection, fat embolism from bone marrow necrosis, pulmonary infarction. Treatment: antibiotics (cephalosporin + macrolide), supplemental oxygen, incentive spirometry, simple or exchange transfusion. Goal Hb after transfusion: 10 g/dL (avoid hyperviscosity above 10-11)

Stroke

Ischemic stroke: 11% cumulative risk by age 20 (without screening) TCD screening and chronic transfusion have dramatically reduced pediatric stroke. Adults: increasing recognition of silent cerebral infarcts, cognitive decline. Acute stroke management: exchange transfusion to HbS <30%.

Splenic Sequestration

Acute pooling of blood in the spleen causing rapid hemoglobin drop. Medical emergency in young children (functional asplenia develops by age 5 in HbSS) May still occur in HbSC patients who retain splenic function into adulthood.

Aplastic Crisis

Parvovirus B19 infection causing transient red cell aplasia. Reticulocyte count drops to near zero. Usually self-limited but may require transfusion.

Priapism

Ischemic priapism in 35% of males with SCD; Urologic emergency if duration >4 hours; Aspiration and irrigation with phenylephrine; Stuttering priapism: recurrent short episodes; hydroxyurea or pseudoephedrine for prevention.

Chronic Complications

Chronic Pain

Central sensitization, avascular necrosis, leg ulcers. Multimodal approach: NSAIDs, gabapentinoids, SNRIs, physical therapy. Opioid therapy: often necessary but complicated by stigma and tolerance. Cognitive behavioral therapy and mindfulness-based approaches.

Chronic Organ Damage

Pulmonary hypertension: elevated TRV >2.5 m/s on echo; associated with mortality. Nephropathy: hyperfiltration in childhood, proteinuria, progressive CKD. ACE inhibitors for proteinuria. CKD-EPI equation overestimates GFR in SCD. Retinopathy: proliferative retinopathy especially in HbSC; annual dilated eye exams. Avascular necrosis: hips and shoulders; may require arthroplasty. Iron overload: from chronic transfusions; chelation with deferasirox or deferoxamine. Leg ulcers: chronic, painful, difficult to heal.

Cardiopulmonary Disease

High-output cardiac state due to chronic anemia; Diastolic dysfunction common; Echocardiography screening for elevated TRV; 6-minute walk test for functional assessment; Right heart catheterization to confirm pulmonary hypertension.

Disease-Modifying Therapies

Hydroxyurea

First-line disease-modifying therapy for all patients with HbSS aged 9 months+. Mechanism: increases HbF production, reduces WBC and platelet counts, improves NO bioavailability. MSH trial (adults): 44% reduction in VOC, reduced ACS, reduced transfusions. BABY HUG trial: benefits in infants even without clinical symptoms. Target: maximum tolerated dose (monitor CBC for neutropenia) Underutilized in adult patients due to misconceptions about toxicity and fertility.

Chronic Transfusion Therapy

Primary indication: stroke prevention (maintain HbS <30%) Simple transfusion vs. exchange transfusion (manual or automated erythrocytapheresis) Iron overload monitoring with ferritin and liver MRI (FerriScan/R2-MRI) Alloimmunization risk: phenotypically matched (C, E, K at minimum) RBCs.

L-Glutamine (Endari)

FDA-approved for reducing VOC frequency (ages 5+) Reduces oxidative stress in sickle RBCs. Modest benefit; used as adjunct to hydroxyurea.

Crizanlizumab (Adakveo)

Anti-P-selectin monoclonal antibody; IV infusion every 4 weeks. SUSTAIN trial: reduced VOC in adults. Post-marketing data less robust; limited pediatric data.

Voxelotor (Oxbryta)

HbS polymerization inhibitor; increases hemoglobin. Improves anemia markers but unclear if reduces VOC. Voluntarily withdrawn from market in 2024 due to lack of clinical benefit evidence in confirmatory trials.

Curative Therapies

Hematopoietic stem cell transplant (HSCT):; Matched sibling donor: >90% cure rate, 5% mortality; Haploidentical transplant: expanding access; Underutilized in adults due to higher transplant-related mortality, GVHD risk; Gene therapy:; Lentiviral vector (Casgevy -- CRISPR/Cas9 editing of BCL11A; Lyfgenia -- lentiviral HbAT87Q) FDA-approved 2023; early results show elimination of VOC; Barriers: cost ($2-3 million), myeloablative conditioning required, limited centers.

The Transition Crisis in SCD

Mortality rate increases 3-fold between ages 18-30. Causes: loss of comprehensive pediatric care, insurance gaps, lack of adult SCD expertise. Many adult hematologists/oncologists have limited SCD training. Pain management stigma is worse in adult emergency departments. Structured transition programs reduce mortality and ED utilization.

Transition-Specific Considerations

Transfer of TCD screening protocols and chronic transfusion plans; Reproductive counseling: hydroxyurea is teratogenic (contraception required); Genetic counseling for reproductive planning; Mental health screening (depression prevalence ~30%); Vocational and educational support; Insurance navigation (Medicaid, disability services).

<image>A pathophysiology illustration of sickle cell vaso-occlusion showing a blood vessel cross-section. Normal red blood cells flow freely on the left side, while on the right side, deoxygenated hemoglobin S polymerizes within red blood cells causing them to become rigid and crescent-shaped. These sickled cells adhere to activated endothelium (with P-selectin and VCAM-1 shown), trapping neutrophils and platelets, occluding the vessel. Downstream tissue shows ischemia and infarction. Labels indicate the targets of crizanlizumab (P-selectin), voxelotor (HbS polymer), and hydroxyurea (HbF induction).</image>

<image>A graph showing the mortality curve in sickle cell disease across age, with a relatively low mortality rate in childhood (ages 0-18) due to comprehensive pediatric care, followed by a sharp spike in mortality between ages 18-30 during the transition period, and continued elevated mortality in adulthood. Annotations highlight the key protective factors lost during transition: TCD screening, comprehensive hematology care, penicillin prophylaxis compliance, and insurance coverage.</image>

<image>A clinical algorithm flowchart for acute chest syndrome management in SCD. Starting with clinical presentation (fever, chest pain, respiratory distress, new pulmonary infiltrate on CXR), branching through initial assessment (vital signs, CBC, reticulocyte count, type and screen, blood cultures), and leading to management steps: supplemental oxygen to maintain SpO2 >95%, empiric antibiotics (cephalosporin plus macrolide), incentive spirometry every 2 hours while awake, simple transfusion if Hb below baseline, and exchange transfusion if rapidly worsening or Hb already at baseline. Decision points for ICU transfer are indicated.</image>

Clinical Pearls

The single most important intervention in pediatric SCD is transcranial Doppler screening to prevent stroke. Hydroxyurea is indicated for ALL patients with HbSS starting at age 9 months -- it is dramatically underutilized in adults. Never transfuse a sickle cell patient to Hb >10 g/dL due to hyperviscosity risk. Acute chest syndrome is the leading cause of death -- always think of it when a VOC patient develops respiratory symptoms or fever. Pain management bias against SCD patients is a documented health disparity that Med-Peds physicians must actively counter. HbSC disease has distinct complications: proliferative retinopathy, avascular necrosis, and splenic sequestration can occur in adulthood. Gene therapy (Casgevy, Lyfgenia) represents the first non-transplant curative option but access is severely limited by cost and infrastructure. The mortality spike in early adulthood is largely preventable with structured transition programs -- this is a Med-Peds opportunity.

References

• Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311-323.
• NHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report. 2014.
• Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography (STOP). N Engl J Med. 1998;339(1):5-11.
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia (MSH). N Engl J Med. 1995;332(20):1317-1322.
• Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021;384(3):252-260.
• DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease. Blood Adv. 2020;4(8):1554-1588.

Read this lecture as Markdown